Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.
about
Predictive value of symptoms for early detection of ovarian cancerChallenging and complex decisions in the management of the BRCA mutation carrierDo nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysisProteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulationA urinary Bcl-2 surface acoustic wave biosensor for early ovarian cancer detection.Progress and challenges in screening for early detection of ovarian cancer.Forth nightly review: hereditary ovarian carcinoma.A hospital-based case-control study of identifying ovarian cancer using symptom index.Ascertainment of familial ovarian cancer in the Aberdeen Genetic Clinic.Gynaecological cancer.MUC16 (CA125): tumor biomarker to cancer therapy, a work in progressDifferential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancerPhase II biomarker trial of a multimarker diagnostic for ovarian cancerRole of tumour markers in monitoring epithelial ovarian cancer.Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.Familial ovarian cancer.Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.Features of ovarian cancer in Lynch syndrome (Review).Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.Laparoscopic management of adnexal masses the opportunities and the risks.Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.Screening for ovarian cancer: recommendation statement.Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider.Paracetamol use and risk of ovarian cancer: a meta-analysisAdnexal masses suspected to be benign treated with laparoscopyThe value of ovarian cancer screening.Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study.Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.Screening for ovarian, prostatic, and testicular cancersRecruitment to multicentre trials--lessons from UKCTOCS: descriptive studyValidation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian CancerGiant serous papillary cystadenoma.Ovarian cancer biomarkers: a focus on genomic and proteomic findings.Use of Biomarkers in Screening for Cancer.Refining Ovarian Cancer Test accuracy Scores (ROCkeTS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer.Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.Accuracy of ovarian and colon cancer risk assessments by U.S. physicians.
P2860
Q24644590-811A4F71-928E-49AF-A25A-93E38BBA95E3Q27026559-60C84DCE-370D-4D0D-8B3B-E0F8229086CDQ28185207-06F90B96-D144-44E6-897F-3C58C0B46F06Q28477301-C703A221-AFF5-47AE-B86E-88FE22408556Q30463771-59F0EDD4-2C7A-4D39-83F9-702238809D9FQ31041170-5FA7A796-46CD-455E-9517-8CB5D2AAE3EDQ33542652-272D5681-1C23-494D-AEF5-B35926341780Q33561005-B31F3AEA-9727-410A-BCC5-CDE9B3A6414AQ33683293-D87D71BE-3270-46FB-BA53-19A94EB37E8EQ33704172-47C0A7BE-610E-4F64-8B12-17AE9A889452Q33713506-E10A6A88-D12C-4707-96B4-ECB48195DA76Q33843741-30FC467A-8B81-4D01-9E2E-2CCB9950AAE1Q33868802-139CEB27-2463-4A21-8A05-A3D551D3C92CQ33903011-B80D0F61-79ED-4A60-BA9E-68AB41E8DA4FQ33964990-23830B30-2897-41A5-BA47-87B9CBEB9970Q34243664-381DA5F0-25FD-45AB-BE15-8DB87866DB91Q34244781-B20E55F2-6F05-49C9-B84E-DA656935229EQ34265940-0C5BACF2-0401-4533-AEB5-D8FB05E69112Q34266010-F4AC87C9-C199-4FAE-B281-DB44DF985182Q34313361-3EF2DB0A-47E6-4F9D-B2D9-FCEF8CC472B3Q34397244-4958D258-3FB6-4892-97BA-F40E1AC38C0CQ34445730-88F98028-D15B-4C3D-B8E9-1355FD4431B8Q34628501-3179F8B4-AA6B-456D-B7CE-94A6989809ABQ34637879-EFB58905-91EF-446B-807D-8B9969D12F4BQ35040690-C31B2A15-0C75-4B2A-BC46-146F2DCDD04CQ35688551-0E616F18-BBA8-4F6C-BE89-DD49720B01DCQ35827624-CB29FF53-D396-4EA1-BBF0-A172D8F8ACC0Q36124571-BD046F0E-93F1-40FE-8FB7-191DFE1D59CBQ36527616-4B392754-7A49-4756-B2AF-B927E51422DAQ36601557-CCFDAEB8-CDB6-404B-97EF-0492C16B67C2Q36620469-9524E1A5-F6F8-497F-8A0F-F960478010EAQ36886776-157BDED6-4973-486A-99F7-02663288B7E5Q36973956-09B12CD1-F224-4F18-8E1C-7B8B4BDC5A73Q37026450-B35E208A-5765-4765-873B-121F63603A22Q37037679-6016C70E-23B8-45E4-A221-A2C2AC2B364AQ37119992-F0EC6C47-4EB9-4FCB-8EB5-0409D994BDB4Q37155019-23FAA186-C107-4FE7-A92C-C7688DA5AC33Q37177372-8FFB5EF9-8001-4FF7-A739-162A96CF8936Q37390397-1EE0AC5A-FC9A-48F0-87C2-F18C054BA10EQ37724409-DB7F6796-6D23-4377-8923-B5EF6C85EF57
P2860
Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.
description
1993 nî lūn-bûn
@nan
1993 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Prevalence screening for ovari ...... asurement and ultrasonography.
@ast
Prevalence screening for ovari ...... asurement and ultrasonography.
@en
type
label
Prevalence screening for ovari ...... asurement and ultrasonography.
@ast
Prevalence screening for ovari ...... asurement and ultrasonography.
@en
prefLabel
Prevalence screening for ovari ...... asurement and ultrasonography.
@ast
Prevalence screening for ovari ...... asurement and ultrasonography.
@en
P2093
P2860
P1433
P1476
Prevalence screening for ovari ...... asurement and ultrasonography.
@en
P2093
Grudzinskas JG
P2860
P304
P356
10.1136/BMJ.306.6884.1030
P407
P577
1993-04-01T00:00:00Z